Arash Hatefi

2.6k total citations · 1 hit paper
57 papers, 2.1k citations indexed

About

Arash Hatefi is a scholar working on Molecular Biology, Genetics and Oncology. According to data from OpenAlex, Arash Hatefi has authored 57 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Molecular Biology, 25 papers in Genetics and 12 papers in Oncology. Recurrent topics in Arash Hatefi's work include RNA Interference and Gene Delivery (30 papers), Virus-based gene therapy research (24 papers) and Advanced biosensing and bioanalysis techniques (13 papers). Arash Hatefi is often cited by papers focused on RNA Interference and Gene Delivery (30 papers), Virus-based gene therapy research (24 papers) and Advanced biosensing and bioanalysis techniques (13 papers). Arash Hatefi collaborates with scholars based in United States, Iran and Canada. Arash Hatefi's co-authors include Brian G. Amsden, Brenda Canine, Yuhua Wang, Hamidreza Ghandehari, Mohammad Ramezani, Alireza Nomani, W. Thomas Shier, Reza Kazemi Oskuee, Ali Dehshahri and Joseph Cappello and has published in prestigious journals such as Biomaterials, Cancer Research and Advanced Drug Delivery Reviews.

In The Last Decade

Arash Hatefi

56 papers receiving 2.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Biodegradable injectable in situ forming drug delivery systems

2002 592 citations Arash Hatefi, Brian G. Amsden Journal of Controlled Release profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Arash Hatefi United States	25	1.1k	630	474	377	332	57	2.1k
Henrique Faneca Portugal	26	1.4k 1.2×	437 0.7×	462 1.0×	399 1.1×	122 0.4×	57	2.1k
Simon C. W. Richardson United Kingdom	21	1.1k 1.0×	446 0.7×	218 0.5×	216 0.6×	173 0.5×	33	2.1k
Miriam Breunig Germany	24	2.3k 2.1×	837 1.3×	623 1.3×	691 1.8×	192 0.6×	53	3.4k
Sung Wan Kim United States	22	1.3k 1.2×	529 0.8×	375 0.8×	302 0.8×	96 0.3×	44	2.0k
Ji Young Yhee South Korea	29	1.2k 1.1×	808 1.3×	180 0.4×	851 2.3×	149 0.4×	63	2.5k
Thomas Merdan Germany	19	1.8k 1.6×	726 1.2×	622 1.3×	363 1.0×	173 0.5×	23	2.5k
Yohei Mukai Japan	32	1.6k 1.4×	398 0.6×	409 0.9×	352 0.9×	311 0.9×	102	3.0k
You-Kyoung Kim South Korea	26	1.3k 1.1×	496 0.8×	528 1.1×	351 0.9×	193 0.6×	53	1.9k
Siddharth Jhunjhunwala India	27	1.4k 1.3×	438 0.7×	307 0.6×	866 2.3×	112 0.3×	56	2.8k
Owen S. Fenton United States	26	3.2k 2.9×	796 1.3×	633 1.3×	855 2.3×	182 0.5×	55	4.6k

Countries citing papers authored by Arash Hatefi

Since Specialization

Citations

This map shows the geographic impact of Arash Hatefi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Arash Hatefi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Arash Hatefi more than expected).

Fields of papers citing papers by Arash Hatefi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Arash Hatefi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Arash Hatefi. The network helps show where Arash Hatefi may publish in the future.

Co-authorship network of co-authors of Arash Hatefi

This figure shows the co-authorship network connecting the top 25 collaborators of Arash Hatefi. A scholar is included among the top collaborators of Arash Hatefi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Arash Hatefi. Arash Hatefi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Li, Geng, et al.. (2025). Natural killer cell engagers for cancer immunotherapy. Frontiers in Oncology. 14. 1483884–1483884. 6 indexed citations

Owji, Hajar, Geng Li, Mohammad Massumi, et al.. (2024). A Novel Tetravalent Bispecific Immune Cell Engager Activates Natural Killer Cells to Kill Cancer Cells without Mediating Fratricide. Antibodies. 13(3). 75–75. 1 indexed citations

Yang, Ge, Hajar Owji, Rick I. Cohen, et al.. (2024). Bispecific immune cell engager enhances the anticancer activity of CD16+ NK cells and macrophages in vitro, and eliminates cancer metastasis in NK humanized NOG mice. Journal for ImmunoTherapy of Cancer. 12(3). e008295–e008295. 13 indexed citations

Vandavasi, Venu Gopal, Ge Yang, Pedro Louro, et al.. (2023). A high affinity and specificity anti-HER2 single-domain antibody (VHH) that targets trastuzumab’s epitope with versatile biochemical, biological, and medical applications. Immunologic Research. 72(1). 103–118. 7 indexed citations

Li, Geng, et al.. (2023). Bispecific killer cell engager with high affinity and specificity toward CD16a on NK cells for cancer immunotherapy. Frontiers in Immunology. 13. 1039969–1039969. 32 indexed citations

Nomani, Alireza, Geng Li, Siavash Yousefi, et al.. (2021). Gadolinium-labeled affibody-XTEN recombinant vector for detection of HER2+ lesions of ovarian cancer lung metastasis using quantitative MRI. Journal of Controlled Release. 337. 132–143. 10 indexed citations

Nomani, Alireza, et al.. (2017). Bioengineering a non-genotoxic vector for genetic modification of mesenchymal stem cells. Biomaterials. 152. 1–14. 15 indexed citations

Wang, Xing, et al.. (2015). Reducing the Visibility of the Vector/DNA Nanocomplexes to the Immune System by Elastin-Like Peptides. Pharmaceutical Research. 32(9). 3018–3028. 26 indexed citations

Khaw, Ban‐An, et al.. (2014). Bispecific antibody complex pre-targeting and targeted delivery of polymer drug conjugates for imaging and therapy in dual human mammary cancer xenografts. European Journal of Nuclear Medicine and Molecular Imaging. 41(8). 1603–1616. 21 indexed citations

10.

Wang, Yuhua, Lu Zhang, Shutao Guo, Arash Hatefi, & Leaf Huang. (2013). Incorporation of histone derived recombinant protein for enhanced disassembly of core-membrane structured liposomal nanoparticles for efficient siRNA delivery. Journal of Controlled Release. 172(1). 179–189. 24 indexed citations

11.

Soltani, Fatemeh, Mojtaba Sankian, Arash Hatefi, & Mohammad Ramezani. (2012). Design and development of a series of recombinant fusion vectors for targeted cancer gene delivery. Research in Pharmaceutical Sciences. 7(5). 1023. 1 indexed citations

12.

Hosseinkhani, Saman, et al.. (2012). Design, engineering and preparation of a multi-domain fusion vector for gene delivery. International Journal of Pharmaceutics. 427(2). 393–399. 43 indexed citations

13.

Hatefi, Arash & Tamara Minko. (2012). Advances in image-guided drug delivery. Drug Delivery and Translational Research. 2(1). 1–2. 7 indexed citations

14.

McCarthy, Helen O., et al.. (2010). Advances with the use of bio-inspired vectors towards creation of artificial viruses. Expert Opinion on Drug Delivery. 7(4). 497–512. 27 indexed citations

15.

Canine, Brenda, et al.. (2010). Development of targeted recombinant polymers that can deliver siRNA to the cytoplasm and plasmid DNA to the cell nucleus. Journal of Controlled Release. 151(1). 95–101. 25 indexed citations

16.

McCarthy, Helen O., Yuhua Wang, Brenda Canine, et al.. (2010). Evaluation of a multi-functional nanocarrier for targeted breast cancer iNOS gene therapy. International Journal of Pharmaceutics. 405(1-2). 196–202. 15 indexed citations

17.

Dehshahri, Ali, Reza Kazemi Oskuee, W. Thomas Shier, Arash Hatefi, & Mohammad Ramezani. (2009). Gene transfer efficiency of high primary amine content, hydrophobic, alkyl-oligoamine derivatives of polyethylenimine. Biomaterials. 30(25). 4187–4194. 108 indexed citations

18.

Hatefi, Arash & Brian G. Amsden. (2002). Biodegradable injectable in situ forming drug delivery systems. Journal of Controlled Release. 80(1-3). 9–28. 592 indexed citations breakdown →

19.

Hatefi, Arash & Brian G. Amsden. (2002). Camptothecin Delivery Methods. Pharmaceutical Research. 19(10). 1389–1399. 144 indexed citations

20.

Hatefi, Arash, et al.. (1996). CHARACTERIZATION AND EVALUATION OF ENTERIC COATED CONTROLLED RELEASE TABLET FORMULATIONS OF DICLOFENAC SODIUM. Acta Pharmaceutica. 46(4). 285–285. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact